Skip to content

Comparison of Ovulation Induction Cycle Outcomes Between Early and Late Dose Increments for Low Dose Gonadotropin Step-up Protocol Among Infertile Women Diagnosed With Polycystic Ovary Syndrome: Prospective Randomised Trial

Comparison of Ovulation Induction Cycle Outcomes Between Early and Late Dose Increments for Low Dose Gonadotropin Step-up Protocol Among Infertile Women Diagnosed With Polycystic Ovary Syndrome: Prospective Randomised Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04528849
Enrollment
160
Registered
2020-08-27
Start date
2020-08-20
Completion date
2022-08-20
Last updated
2020-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female, Polycystic Ovary Syndrome

Keywords

Polycystic ovary syndrome, Infertility, Low dose step-up, Gonadotropin, Ovulation induction

Brief summary

Low dose gonadotropin step-up ovulation induction treatment is the universally accepted and utilized teratment protocol for infertile women diagnosed with polycystic ovary syndrome (PCOS). First dose increment is advised on 14th day of ovarian stimulation with gonadotropins to decrease multiple follicle generation and cycle cancellation rates. However, clinicians impatiently increase gonadotropin dose on 7th day of stimulation without strong scientific evidence. This randomised controlled study will be the first study which will compare safety and ovulation induction cyle outcomes of early and late dose increments among infertile women diagnosed with PCOS.

Detailed description

Low dose gonadotropin step-up ovulation induction treatment is the universally accepted and utilized teratment protocol for infertile women diagnosed with polycystic ovary syndrome. First dose increment is advised on 14th day of ovarian stimulation with gonadotropins to decrease multiple follicle generation and cycle cancellation rates. However, clinicians impatiently increase gonadotropin dose on 7th day of stimulation without strong scientific evidence. This randomised controlled study will be the first study which will compare safety and ovulation induction cyle outcomes of early and late dose increments among infertile women diagnosed with polycystic ovary syndrome. We will start low dose step-up ovulation induction treatment by using 50 IU recombinant FSH for 21-39 years old non- obese patients (BMI \<30 kg/m2) diagnosed with PCOS and . We will perform folliculometry on 7th day of ovulation induction. In case of absence for at least one \>10 mm dominant follicle, we will randomise these women by using blind envelope selection method for assignment of early or late dose incerement groups. Half of the patients will receive 25 IU dose increment on 7th day of ovulation induction, remaining half will receive dose increment on 14th day of ovulation induction. We will continue ovarian stimulation without any other dose increment until 35th day of stimulation as deadline time restriction. We will perform folliculometry and serum estradiol measurement intermittently during ovulation induction. We will record ovulation induction cycle outcomes and clinical pregnancy results of the study group following finalization for treatment cyle of each patient. We will compare ovulation induction cycle outcomes of these two dose increment groups.

Interventions

DRUGGonadotropin dose increment timing

Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.

Sponsors

Saglik Bilimleri Universitesi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

Infertile women who have been diagnosed with PCOS based on Rotterdam criteriae and who have not succeeded to get pregnant by using oral ovulation induction agents and whose BMI levels are \<30 kg/m2 will be included to the study.

Exclusion criteria

Infertile women with tubal diseases, male factor infertility, endometriosis, previous pelvic surgery history, chronic systemic disease, BMI levels\>30 kg/m2 and who are not voluntary to attend to the study will be excluded from the study.

Design outcomes

Primary

MeasureTime frameDescription
Number of preovulatory follicles35 daysNumber of \>14 mm sized follicles at the end of the ovulation induction treatment

Secondary

MeasureTime frameDescription
Biochemical pregnancy rate2 weeks after ovulation triggeringSerum pregnancy test will be performed 2 weeks after ovulation triggering
Clinical pregnancy rate3 weeks after ovulation triggeringClinical pregnancy rate which will be evaluated 3 weeks after ovulation triggering
Cycle length in days7-35 daysTotal number of ovulation induction days until ovulation triggering
Cycle cancellation35 daysCycle cancellation due to \>=3 preovulatory follicles (\>14 mm in size) at the end of the ovulation induction treatment
Multiple pregnancy rate3 weeks after ovulation triggeringMultiple pregnancy rate which will be evaluated 3 weeks after ovulation triggering

Countries

Turkey (Türkiye)

Contacts

Primary ContactSerkan Kahyaoglu, M.D
serkan.kahyaoglu@sbu.edu.tr+905058868040

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026